The Cardiolynx technology employs specific vasodilating chemical linkers as grafts onto or in combination with established cardiovascular drugs resulting in a dual mode of action: the original mode of action of the established product plus the synergistic vasodilative mode.
Dr. Dirk Sartor, CEO of Cardiolynx, commented: “CLC-1280 is active in preclinical models of vasodilatation and has the potential to reduce blood pressure and prevent or reduce angina pectoris thus improving the standard care of this chronic and debilitating condition. The new patent strengthens Cardiolynx’s intellectual property portfolio which includes four patent families with pending applications worldwide.”
Cardiolynx recently presented preclinical data of CLC-1280 at the 5th Annual European Life Sciences Forum in Zurich, March 6-7, 2012, Switzerland. The data demonstrated the vasodilatory efficacy of CLC-1280 in two animal models.
About Cardiolynx
Cardiolynx ltd. is a biotechnology company focused developing innovative cardio-metabolic therapies. Cardiolynx’ vision is to develop superior medical compounds aimed at maximizing the potential for late lifecycle management of established products. The current focus is on three indications with solid growth potential resulting from the increasing prevalence of cardiovascular diseases in the aging population. Cardiolynx has successfully filed its specific intellectual property for patent protection and is developing a series of drug candidates across the cardio-metabolic disease areas. Cardiolynx is financed by ErfindungsVerwertung AG EVA, Basel and private investors. The company was founded in 2009.
0Comments
Please login or sign up to comment.
Commenting guidelines